Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 1493247

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1493247

DNases, Ligases, And RNA Polymerases Market Size, Share & Trends Analysis Report By Application (DNases-Biopharmaceutical Processing, Ligases- ligonucleotide Synthesis), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

DNases, Ligases, And RNA Polymerases Market Growth & Trends:

The global DNases, ligases, and RNA polymerases market size is expected to reach USD 1.62 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 10.63% from 2024 to 2030. Increasing research and development expenditure is one of the key factors fueling market growth. Furthermore, rising biopharmaceutical production along with a focus on DNA-related innovations is expected to positively impact the global DNases market growth over the forecast period.

For instance, in June 2020, Alphazyme and Codexis entered into a strategic partnership to provide novel enzymes for diagnostics and research. DNases have continued to garner a significant market share in recent years owing to factors such as an increase in the adoption of DNA enzymes related to pharmaceuticals, which are essential for the treatment of various chronic disorders and digestive diseases. In addition, developments in the biotechnology and pharmaceutical fields, such as the introduction of genetic and protein engineering, have helped in expanding applications of enzymes, which is expected to offer lucrative growth opportunities in the forecast period.

An increase in R&D investments to develop ligases as the target for therapeutic applications in cancer is estimated to drive the segment in the forecast period. In addition, strategic activities by major manufacturers will offer lucrative growth opportunities in the projected period. Other factors augmenting segment growth include advancements in healthcare, increasing demand for modernization in the field of medical academics and life sciences, growing investments by governments to develop genomic technologies, and a surge in the demand for oligonucleotide synthesis by private and public research firms.

The COVID-19 pandemic situation has offered lucrative opportunities for RNA polymerase applications. Currently, there are over 150 vaccines and therapeutics that either use mRNA in their production processes or are based on mRNA molecules, which are being assessed for the treatment of a wide range of indications. Many mRNA vaccines are approved for emergency use in many countries across the globe.

For instance, Moderna's mRNA-1273 and BioNTech/ Pfizer BNT-162 vaccines have been approved for use across various regions globally. Moreover, there are instances of huge capital investments for the development of mRNA vaccines. For instance, in June 2021, Sanofi declared an investment of around USD 452.12 annually for its mRNA vaccines development center.

DNases, Ligases, And RNA Polymerases Market Report Highlights:

  • By DNAse application, the other applications segment dominated the market in 2023 due to a rise in DNA-based research, an increase in research funding, and reliable utility of DNase in applications
  • By ligase application, the other applications segment held the maximum share in 2023. Certain factors such as the rising use of ligases in gene therapies and growth in DNA sequencing are expected to play a major role in the segment growth during the forecast period
  • By RNA polymerases application, mRNA production dominated the market in 2023 due to increasing demand for mRNA-based vaccines for COVID-19 and research activities. For instance, Moderna is set to expand its mRNA vaccine pipeline with three new development programs. The programs will target the varicella-zoster virus (VSV), herpes simplex virus (HSV), and a novel checkpoint cancer vaccine
  • North America dominated the global market in 2023 owing to increasing demand for gene therapy, rise in the number of genetic disorders and cancer, the presence of research institutes, rising research funding for research on novel gene therapy, and rise in the demand for DNA-based vaccine production for COVID-19
  • Asia Pacific is expected to grow considerably in the future owing to the rising prevalence of genetic disorders, rising demand for gene therapy, and high population density
Product Code: GVR-4-68039-982-9

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. DNases Application
    • 1.2.2. Ligases Application
    • 1.2.3. RNA Polymerases Application
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. DNases, Ligases, And RNA Polymerases Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing academic and industrial interest in mRNA technology
      • 3.2.1.2. Advancements in biotechnology and molecular biology
      • 3.2.1.3. Increasing demand for gene therapy
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory challenges related to DNases, ligases, And RNA polymerases
  • 3.3. DNases, Ligases, And RNA Polymerases Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. DNases, Ligases, And RNA Polymerases Market: DNases Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global DNases, Ligases, And RNA Polymerases Market DNases Application Movement Analysis
  • 4.3. Global DNases, Ligases, And RNA Polymerases Market Size & Trend Analysis, by DNases Application, 2018 to 2030 (USD Million)
  • 4.4. Biopharmaceutical Processing
    • 4.4.1. Biopharmaceutical processing market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Other Applications
    • 4.5.1. Other applications market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. DNases, Ligases, And RNA Polymerases Market: Ligases Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global DNases, Ligases, And RNA Polymerases Market Ligases Application Movement Analysis
  • 5.3. Global DNases, Ligases, And RNA Polymerases Market Size & Trend Analysis, by Ligases Application, 2018 to 2030 (USD Million)
  • 5.4. Oligonucleotide Sysnthesis
    • 5.4.1. Oligonucleotide synthesis market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Other Applications
    • 5.5.1. Other applications methylation market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. DNases, Ligases, And RNA Polymerases Market: RNA Polymerases Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global DNases, Ligases, And RNA Polymerases Market RNA Polymerases Application Movement Analysis
  • 6.3. Global DNases, Ligases, And RNA Polymerases Market Size & Trend Analysis, by RNA Polymerases Application, 2018 to 2030 (USD Million)
  • 6.4. mRNA Production
    • 6.4.1. mRNA production market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Other Applications
    • 6.5.1. Other applications market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. DNases, Ligases, And RNA Polymerases Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Norway
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Regulatory framework
      • 7.5.8.3. Competitive scenario
      • 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Mexico
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Thermo Fisher Scientific, Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Merck KGaA
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Agilent Technologies, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Promega Corporation
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. New England Biolabs
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. RayBiotech, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. BioVision, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. ABclonal, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. QIAGEN N.V.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Takara Bio, Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Abnova Corporation.
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Calzyme
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Product benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. ArcticZymes Technologies
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Product benchmarking
      • 8.4.13.4. Strategic initiatives
    • 8.4.14. Worthington Biochemical Corporation
      • 8.4.14.1. Company overview
      • 8.4.14.2. Financial performance
      • 8.4.14.3. Product benchmarking
      • 8.4.14.4. Strategic initiatives
    • 8.4.15. MBL International
      • 8.4.15.1. Company overview
      • 8.4.15.2. Financial performance
      • 8.4.15.3. Product benchmarking
      • 8.4.15.4. Strategic initiatives
    • 8.4.16. MyBioSource
      • 8.4.16.1. Company overview
      • 8.4.16.2. Financial performance
      • 8.4.16.3. Product benchmarking
      • 8.4.16.4. Strategic initiatives
    • 8.4.17. BPS Bioscience Inc.
      • 8.4.17.1. Company overview
      • 8.4.17.2. Financial performance
      • 8.4.17.3. Product benchmarking
      • 8.4.17.4. Strategic initiatives
    • 8.4.18. Sino Biological
      • 8.4.18.1. Company overview
      • 8.4.18.2. Financial performance
      • 8.4.18.3. Product benchmarking
      • 8.4.18.4. Strategic initiatives
    • 8.4.19. Novus Biologicals
      • 8.4.19.1. Company overview
      • 8.4.19.2. Financial performance
      • 8.4.19.3. Product benchmarking
      • 8.4.19.4. Strategic initiatives
Product Code: GVR-4-68039-982-9

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Key funding for mRNA R&D in 2020 - 2022
  • Table 3 Clinical development of mRNA vaccine candidates against COVID-19
  • Table 4 Global DNases, ligases, and RNA polymerases market, by region, 2018 - 2030 (USD Million)
  • Table 5 Global DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 6 Global DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 7 Global DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 8 Global DNases, ligases, and RNA polymerases market, 2018 - 2030 (USD Million)
  • Table 9 North America DNases, ligases, and RNA polymerases market, by country, 2018 - 2030 (USD Million)
  • Table 10 North America DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 11 North America DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 12 North America DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 13 U.S. DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 14 U.S. DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 15 U.S. DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 16 Canada DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 17 Canada DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 18 Canada DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 19 Europe DNases, ligases, and RNA polymerases market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 21 Europe DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 22 Europe DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 23 Germany DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 24 Germany DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 25 Germany DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 26 UK DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 27 UK DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 28 UK DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 29 France DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 30 France DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 31 France DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 32 Italy DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 33 Italy DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 34 Italy DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 35 Spain DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 36 Spain DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 37 Spain DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 38 Denmark DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 39 Denmark DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 40 Denmark DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 41 Sweden DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 42 Sweden DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 43 Sweden DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 44 Norway DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 45 Norway DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 46 Norway DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific DNases, ligases, and RNA polymerases market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 51 China DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 52 China DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 53 China DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 54 Japan DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 55 Japan DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 56 Japan DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 57 India DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 58 India DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 59 India DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 60 South Korea DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 61 South Korea DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 62 South Korea DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 63 Australia DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 64 Australia DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 65 Australia DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 66 Thailand DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 67 Thailand DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 68 Thailand DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 69 Latin America DNases, ligases, and RNA polymerases market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 71 Latin America DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 72 Latin America DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 73 Brazil DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 74 Brazil DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 75 Brazil DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 76 Mexico DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 77 Mexico DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 78 Mexico DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 79 Argentina DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 80 Argentina DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 81 Argentina DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 82 MEA DNases, ligases, and RNA polymerases market, by country, 2018 - 2030 (USD Million)
  • Table 83 MEA DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 84 MEA DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 85 MEA DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 86 South Africa DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 87 South Africa DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 88 South Africa DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 92 UAE DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 93 UAE DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 94 UAE DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 95 Kuwait DNases, ligases, and RNA polymerases market, by DNases application, 2018 - 2030 (USD Million)
  • Table 96 Kuwait DNases, ligases, and RNA polymerases market, by ligases application, 2018 - 2030 (USD Million)
  • Table 97 Kuwait DNases, ligases, and RNA polymerases market, by RNA polymerases application, 2018 - 2030 (USD Million)
  • Table 98 Key companies undergoing expansions
  • Table 99 Key companies undergoing acquisitions
  • Table 100 Key companies undergoing expansions
  • Table 101 Key companies undertaking new launch
  • Table 102 Key companies undertaking new launch

List of Figures

  • Fig. 1 DNases, ligases, and RNA polymerases market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validation & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market snapshot
  • Fig. 13 Segment snapshot - 1
  • Fig. 14 Segment snapshot - 2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Biotechnology market value, 2023 (USD billion)
  • Fig. 17 Market trends & outlook
  • Fig. 18 Gene therapies in clinical trials in 2022 globally
  • Fig. 19 PESTEL analysis
  • Fig. 20 Porter's five forces analysis
  • Fig. 21 DNases market: Application outlook & key takeaways
  • Fig. 22 DNases market: Application movement analysis
  • Fig. 23 Global biopharmaceutical processing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global other applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Ligases market: Application outlook & key takeaways
  • Fig. 26 Ligases market: Application movement analysis
  • Fig. 27 Global oligonucleotide synthesis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Global other applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 RNA polymerases market: Application outlook & key takeaways
  • Fig. 30 RNA polymerases market: Application movement analysis
  • Fig. 31 Global mRNA production market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Global other applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Regional marketplace outlook, 2023 & 2030, (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 U.S. DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 Canada DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Europe DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 Germany DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 UK DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 France DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Italy DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Spain DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Denmark DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Norway DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Sweden DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Asia Pacific DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Japan DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 China DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 India DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Australia DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Thailand DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 South Korea DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Singapore DNases, Ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Latin America DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Brazil DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Mexico DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Argentina DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 MEA DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Africa DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Saudi Arabia DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 UAE DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Kuwait DNases, ligases, and RNA polymerases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Market participant categorization
  • Fig. 89 Global DNases, ligases, and RNA polymerases market heat map analysis, 2023
  • Fig. 90 Strategic framework
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!